Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Utah for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Utah only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Utah (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Diana Banks (NPI 1174543060)

Field	Value
Entity Type	Individual
Organization	Diana Banks
Address	370 E 9th Ave Ste 106
City	Salt Lake City
State	UT
ZIP	84103
Taxonomy	Neurology Physician
NPI Enumerated	July 20, 2006

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

This provider bills exclusively to Medicare in the available data set: total Medicare revenue is $1.6M and there is no Medicaid billing on file. That makes the practice effectively single-payer in scope based on submitted claims, leaving revenue concentrated in Medicare reimbursements rather than split across public payers.

Revenue is extremely concentrated in a very small number of HCPCS/CPT items: the precomputed top 3 Medicare codes account for 99.2% of this provider's total Medicare revenue. In particular, J2323 represents $1.2M (75.8% of Medicare revenue) and J2350 represents $356.4K (22.7% of Medicare revenue), together forming the overwhelming bulk of receipts.

The code mix and descriptions indicate an infusion-centered neurology practice focused on high-cost monoclonal antibody therapies for neurologic disease: J2323 (natalizumab) and J2350 (ocrelizumab) are the primary revenue drivers, and the presence of 96365 (initial IV infusion up to one hour) supports an on-site infusion administration workflow. This pattern is consistent with a clinical service line built around in-office biologic infusions rather than a typical E/M–heavy outpatient clinic.

J2323 performance versus national peers shows a relatively prominent position within a small peer set: the provider reported 66K claims for J2323 with an $18 avg paid/claim and $1.2M revenue, ranking #4 of 40 providers nationally and listed at the 92th percentile while the descriptive label is “typical, unremarkable volume for this code.” That combination indicates the provider is a leading biller for J2323 among the limited number of providers who report it, even though the accompanying descriptor characterizes the activity as typical.

By contrast, J2350 performance is modest relative to peers: the provider reported 8.1K claims for J2350 with a $44 avg paid/claim and $356.4K revenue, ranking #84 of 105 providers nationally and at the 19th percentile with the label “typical, unremarkable volume for this code.” This suggests the practice participates in ocrelizumab administration but is not a top national biller for that product.

The administrative infusion code 96365 appears in the mix but contributes only $10.6K (0.7% of Medicare revenue) from 231 claims at a $46 avg paid/claim, ranking #1463 of 8873 providers nationally and at the 83th percentile with the label “typical, unremarkable volume for this code.” This shows that while infusion administration is present and aligns with the drug-focused revenue, the bulk of dollars come from the drugs themselves rather than procedural revenue.

Traditional evaluation-and-management codes (for example 99204, 99213, 99214) generate only small amounts of revenue relative to infusions (99204 = $4.2K, 99213 = $2.8K, 99214 = $1.5K), indicating the practice’s financial model is dominated by drug administration rather than office visit billing. These E/M volumes imply the provider does perform new and established patient visits, but they are a minor component of total Medicare receipts.

The NPI was enumerated on 2006-07-20 (~20 years ago), indicating a long tenure in the Medicare program that likely reflects an established practice infrastructure for delivering infusion therapies. Coupled with the absence of Medicaid billing on file, the provider has an established, Medicare-focused infusion business that could be sensitive to changes in Medicare coverage, reimbursement policy, or drug utilization patterns.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

11 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2323	Injection, natalizumab, 1 mg	66,020	$20	$1.2M
J2350	Injection, ocrelizumab, 1 mg	8,100	$40	$356.4K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	230	$50	$10.6K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	40	$110	$4.2K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	50	$60	$2.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	40	$60	$2.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	20	$80	$1.5K
96415	In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the…	40	$20	$770
96375	Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the…	50	$10	$470
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	80	$1	$240

Showing 1–10 of 11

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 11 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Utah Distribution

Diana Banks — 3 of 11 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Utah

Full comparison — all codes billed, vs. state median

11 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2323	1	10	32,130	$20	$741.7K
J2350	1	10	5,100	$40	$221.6K
96413	43	50	100	$90	$13.8K
99214	3,666	4,080	80	$80	$11.6K
99213	2,253	3,680	60	$50	$6.4K
96365	13	80	90	$40	$5.2K
99204	592	1,790	30	$100	$4.1K
96415	26	40	60	$20	$2K
96375	19	30	50	$10	$990
J2930	1	10	30	$1	$140

Showing 1–10 of 11

Related Providers

Other providers that share a Tax Identification Number (TIN) with Diana Banks, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dr John Foley LLC	UT	Neurology Physician	$0	$3.9M
John Foley	UT	Neurology Physician	$789.8K	$608K
April Erwin	UT	Neurology Physician	$1.2M	$0
Timothy West	UT	Neurology Physician	$664.5K	$0
Viktoria Kaplan	UT	Neurology Physician	$517.8K	$0
Stacey Steeves	UT	Neurology Physician	$196.4K	$0

Nearby Providers

Other providers in the same ZIP code as Diana Banks, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ihc Health Services Inc	UT	Rehabilitation Clinic/Center	$0	$2.5M
Ihc Health Services Inc	UT	Psychiatry Physician	$0	$830.1K
Shriners Hospitals For Children	UT	Children's Hospital	$0	$605.5K
Daniel Preece	UT	Foot & Ankle Surgery Podiatrist	$267.1K	$0
Avenues Surgery Center, LLC	UT	Ambulatory Surgical Clinic/Center	$236K	$0
Jeffrey Osborn	UT	Cardiovascular Disease Physician	$136.2K	$0
Caleb Sturge	UT	Diagnostic Radiology Physician	$101.3K	$0
Yvonne Hsu	UT	Gynecology Physician	$84.2K	$0
Darren Groberg	UT	Foot & Ankle Surgery Podiatrist	$68K	$0
Richard Matern	UT	Urology Physician	$61.2K	$0

Diana Banks — Billing Profile & Reimbursement Data

Sign up for Diana Banks — Billing Profile & Reimbursement Data policy alerts

Diana Banks — Billing Profile & Reimbursement Data

Sign up for Diana Banks — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References